Belen San Antonio

TL;DR: Pemetrexed-cisplatin combined with TRT followed by consolidation pemetrexe was not superior to standard chemoradiotherapy for stage III unresectable nonsquamous non-small-cell lung cancer.

TL;DR: Abemaciclib when combined with ET is the first CDK4/6 inhibitor to demonstrate a significant improvement in IDFS in patients with HR+, HER2− node-positive EBC at high risk of early recurrence.

TL;DR: Continuation maintenance pemetrexed had comparable survival and toxicity profiles in the elderly and non-elderly subgroups, however, grade 3/4 anemia and neutropenia were numerically higher for elderly patients.

TL;DR: In the monarchE trial as discussed by the authors , an open-label, randomised, phase 3 trial, adult patients (aged ≥18 years) who had hormone receptor-positive, HER2-negative, node-positive early breast cancer at a high risk of recurrence with an Eastern Cooperative Oncology Group performance status of 0 or 1 were recruited from 603 sites including hospitals and academic and community centres in 38 countries.

TL;DR: Overall, the incidence of low-grade fatigue, anemia, and neutropenia decreased with long-term pemetrexed exposure; however, renal events increased across treatment arms and EQ-5D analyses demonstrated no treatment-by-time interaction or overall treatment differences between the 2 arms.